| Date | Price Target | Change |
| 2022-07-04 | $4.24 | 7.70 % |
| 2022-07-05 | $4.46 | 5.02 % |
| 2022-07-06 | $4.58 | 2.88 % |
| 2022-07-07 | $4.67 | 1.88 % |
Where can I buy IMVT shares?
Shares of IMVT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
Did immunovant's (IMVT) insider buyers get rich last week?
Immunovant, Inc. ( NASDAQ:IMVT ) insiders who purchased shares in the last 12 months were richly rewarded last week... Immunovant's (IMVT) earnings miss estimates in second-quarter fiscal 2022 (ended Sep 30, 2021).
What is the average price target of a stock with a forecast?
The average price target is $14.25 with a high forecast of $20.00 and a low forecast of $9.00. The average price target represents a 103.86% change from the last price of $6.99. The highest, average, and lowest price target of all analysts.
Is IMVT a good stock to Buy?
Out of 3 analysts, 0 (0%) are recommending IMVT as a Strong Buy, 1 (33.33%) are recommending IMVT as a Buy, 2 (66.67%) are recommending IMVT as a Hold, 0 (0%) are recommending IMVT as a Sell, and 0 (0%) are recommending IMVT as a Strong Sell.
Why did IMVT stock drop?
IMVT, -5.30% plunged 49.8% to pace all premarket losers Tuesday, after the biopharmaceutical company said it has paused dosing in its phase 2b trial for IMVT-1401, a treatment for thyroid eye disease (TED).
Will IMVT go up?
Immunovant Inc (NASDAQ:IMVT) The 9 analysts offering 12-month price forecasts for Immunovant Inc have a median target of 12.00, with a high estimate of 16.00 and a low estimate of 4.00. The median estimate represents a +202.27% increase from the last price of 3.97.
Is Roivant Sciences a good investment?
Roivant Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.
Should I buy or sell Immunovant stock right now?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immunovant in the last year. There are currently 1 sell rating, 2 hold rat...
What is Immunovant's stock price forecast for 2022?
6 Wall Street analysts have issued twelve-month price targets for Immunovant's shares. Their forecasts range from $6.00 to $16.00. On average, they...
How has Immunovant's stock performed in 2022?
Immunovant's stock was trading at $8.52 on January 1st, 2022. Since then, IMVT shares have decreased by 60.2% and is now trading at $3.39. View th...
When is Immunovant's next earnings date?
Immunovant is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022. View our earnings forecast for Immunovant .
How were Immunovant's earnings last quarter?
Immunovant, Inc. (NASDAQ:IMVT) issued its earnings results on Friday, November, 5th. The company reported ($0.35) EPS for the quarter, missing anal...
Who are Immunovant's key executives?
Immunovant's management team includes the following people: Dr. Frank M. Torti M.B.A. , M.D., MBA, Exec. Chairperson of the Board (Age 43, Pay $...
Who are some of Immunovant's key competitors?
Some companies that are related to Immunovant include Krystal Biotech (KRYS) , Revolution Medicines (RVMD) , Allogene Therapeutics (ALLO) , Imm...
What other stocks do shareholders of Immunovant own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Immunovant investors own include Salesforce (CRM) , NVIDI...
What is Immunovant's stock symbol?
Immunovant trades on the NASDAQ under the ticker symbol "IMVT."
About Immunovant
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases.
Immunovant (NASDAQ:IMVT) Frequently Asked Questions
10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Immunovant in the last twelve months. There are currently 1 sell rating, 5 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Immunovant stock.
Component Grades
We have 9 different ratings for every stock to help you appreciate its future potential. You can unlock it all now.
The Trend in the Analyst Price Target
IMVT's average price target has moved down $8.88 over the prior 28 weeks.
The Trend in the Broker Recommendations
IMVT's average broker recommendation rating improved by 0.69 over the prior 92 days.
How to access Immunovant webcast?
To access the webcast, please visit Immunovant’s website at www.immunovant.com. Participants may also dial in using the numbers provided below: Toll Free: 1-877-407-9039Toll/International: 1-201-689-8470 An archived webcast recording will be available on the Immunovant’s website for a limited time.
What is the net loss for the company in 2021?
Other increases include higher legal, professional, and other administrative costs to support our personnel growth and operations as a public company. Net Loss: Net loss was $28.2 million ($0.29 per common share) for the three months ended March 31, 2021, compared to $20.6 million ($0.38 per common share) for the three months ended March 31, 2020.
Stock Price Forecast
The 8 analysts offering 12-month price forecasts for Immunovant Inc have a median target of 12.00, with a high estimate of 20.00 and a low estimate of 7.00. The median estimate represents a +112.77% increase from the last price of 5.64.
Analyst Recommendations
The current consensus among 9 polled investment analysts is to Buy stock in Immunovant Inc. This rating has held steady since February, when it was unchanged from a Buy rating. Move your mouse over past months for detail
Signals & Forecast
A buy signal was issued from a pivot bottom point on Monday, February 14, 2022, and so far it has risen 1.67%. Further rise is indicated until a new top pivot has been found. Some negative signals were issued as well, and these may have some influence on the near short-term development. The Immunovant, Inc.
Support, Risk & Stop-loss
Immunovant, Inc. finds support from accumulated volume at $5.46 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
Is Immunovant, Inc. stock A Buy?
Immunovant, Inc. holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.
Insiders are very positive buying more shares than they are selling in Immunovant, Inc
In the last 100 trades there were 85.95 million shares bought and 11.36 million shares sold. The last trade was done 25 days ago by Levine Mark S. who bough 383 thousand shares. The large amount of stocks bought compared to stocks sold indicate that the insiders believe there is a potential good upside.
Golden Star Signal
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
About IMVT
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases.
Analyst Forecast
According to 10 analysts, the average rating for Immunovant stock is "Buy." The 12-month stock price forecast is 14.50, which is an increase of 164.60% from the latest price.
News
NEW YORK, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announ...
